Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 10/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CPA1 | P15085 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3446401 | 1.00 | CTSA (0.44) | CTSAGAAALDH1A1CNR1LMNA | |
| SCHEMBL15206127 | 0.89 | CTSA (0.41) | CTSAGAAALDH1A1CNR1CPA1 | |
| SCHEMBL15206125 | 0.89 | CTSA (0.41) | CTSAGAAALDH1A1CNR1CPA1 | |
| SCHEMBL10089992 | 0.87 | LMNA (0.50) | CTSAGAAALDH1A1CNR1LMNA | |
| SCHEMBL10217090 | 0.80 | ATM (0.41) | CTSAGAAALDH1A1CNR1 | |
| SCHEMBL3446517 | 0.80 | CTSA (0.48) | CTSALMNAMAPT | |
| SCHEMBL3446529 | 0.79 | CNR2 (0.48) | CTSAALDH1A1CNR1CPA1 | |
| SCHEMBL3446534 | 0.79 | CNR2 (0.48) | CTSAALDH1A1CNR1CPA1 | |
| SCHEMBL168304 | 0.78 | CTSA (0.47) | CTSALMNAMAPT | |
| Hydrochloric Acid SCHEMBL11798564 | 0.77 | CNR1 (0.40) | CTSAGAAALDH1A1CNR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9180120-B2 | Substituted N-phenethyltriazoloneacetamides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| CN-102438990-B | Substituted 2-acetamido-5-aryl-1, 2, 4-triazolones and use thereof | BAYER SCHERING PHARMA AG | 2014-08-20 | — | — | CN | disclosed |
| US-8796324-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| CN-103864704-A | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER SCHERING PHARMA AG | 2014-06-18 | — | — | CN | disclosed |
| US-20130225646-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8202895-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-19 | — | — | US | disclosed |
| CN-102438990-A | Substituted 2-acetamido-5-aryl-1, 2, 4-triazolones and use thereof | BAYER SCHERING PHARMA AG | 2012-05-02 | — | — | CN | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | CTSA 266/4885GAA 292/4885ALDH1A1 173/4885 |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | CTSA 266/4885GAA 292/4885ALDH1A1 173/4885 |
| US-20130225646-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | TNNT2, TNNI3, PNMT | CTSA 76/4885GAA 755/4885ALDH1A1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.